Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Bookmark
Print
This page was added to your COO of Blueprint Medicines Corp (30-Year Financial, Insider Trades) Kate Haviland (insider trades) sold 7,763 shares of BPMC on 01/10/2020 at an average price of $85.16 a share. The total sale was $661,097.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667. Blueprint Medicines Corp has a market cap of $3.78 billion; its shares were traded at around $76.77 with and P/S ratio of 231.22. GuruFocus has detected 1 severe warning sign with Blueprint Medicines Corp. .
Directors and Officers Recent Trades:
- Director George Demetri sold 568 shares of BPMC stock on 01/10/2020 at the average price of $85. The price of the stock has decreased by 9.68% since.
- COO Kate Haviland sold 7,763 shares of BPMC stock on 01/10/2020 at the average price of $85.16. The price of the stock has decreased by 9.85% since.
- Director George Demetri sold 1,705 shares of BPMC stock on 01/07/2020 at the average price of $80.59. The price of the stock has decreased by 4.74% since.
- Chief Scientific Officer Marion Dorsch sold 4,600 shares of BPMC stock on 12/19/2019 at the average price of $79. The price of the stock has decreased by 2.82% since.
- Chief Medical Officer Anthony L. Boral sold 10,000 shares of BPMC stock on 12/17/2019 at the average price of $76.57. The price of the stock has increased by 0.26% since.
- Warning! GuruFocus has detected 5 Warning Signs with BPMC. Click here to check it out.
- BPMC 30-Year Financial Data
- The intrinsic value of BPMC
- Peter Lynch Chart of BPMC
For the complete insider trading history of BPMC, click here
.
Subscribe
via Email
Subscribe RSS
